

Evaluation of the New Medicine Service

Submission date 05/07/2012	Recruitment status No longer recruiting	<input checked="" type="checkbox"/> Prospectively registered <input checked="" type="checkbox"/> Protocol
Registration date 05/07/2012	Overall study status Completed	<input type="checkbox"/> Statistical analysis plan <input checked="" type="checkbox"/> Results
Last Edited 27/10/2022	Condition category Other	<input type="checkbox"/> Individual participant data

Plain English summary of protocol
Not provided at time of registration

Contact information

Type(s)
Scientific

Contact name
Dr Matthew Boyd

Contact details
School of Pharmacy
University Park
Nottingham
United Kingdom
NG7 2RD
+44 (0)115 9515061
matthew.boyd@nottingham.ac.uk

Additional identifiers

ClinicalTrials.gov (NCT)
NCT01635361

Protocol serial number
12494

Study information

Scientific Title
Understanding and appraising the New Medicine Service in the NHS in England

Study objectives

About 25% medicines prescribed for longterm conditions are not taken as directed, and approximately 15% people receiving a new medicine take few, if any, doses. The New Medicines Service (NMS) is a community pharmacy service that started in England in October 2011 which involves the pharmacist providing additional support to patients starting a new medicine for some breathing problems (asthma & chronic obstructive pulmonary disease [COPD]), high blood pressure, adult onset diabetes or medicines which reduce blood clotting. It aims to improve the way patients take their medicines improving outcomes and reducing costs to the NHS.

Ethics approval required

Old ethics approval format

Ethics approval(s)

First MREC, 02/05/2012 ref: 12/WM/0096

Study design

Randomised interventional trial

Primary study design

Interventional

Study type(s)

Quality of life

Health condition(s) or problem(s) studied

All diseases

Interventions

The effectiveness and cost effectiveness of the NMS will be assessed using a research study where some people will receive the NMS, and some wont, in order to look at the effect of the NMS on problems with their medicines, medicines taking and use of the NHS in general. Data will be collected in the East Midlands, South Yorkshire and London areas. 500 patients will be recruited from a range of different pharmacies and follow them up at 6, 10 and 26 weeks after starting their new medicine to assess effects on medicines taking behaviour, patients reported problems with medicines, referrals to their GP and use of NHS resources. The data gathered will be compared with that being collected routinely by all pharmacies in England to provide wider estimates of cost-effectiveness.

The study will also explore how the NMS service is being implemented by pharmacies. A sample of patients from the main study will be followed in more detail. This will involve recording the consultations with the pharmacist and also interviewing patients about their experience of the service. The patients GPs will be interviewed to investigate their views of the service. The trialists will also try to understand why people decline the invitation for the NMS.

Follow Up Length: 6 months.

Intervention Type

Other

Phase

Not Applicable

Primary outcome(s)

Medicines adherence measured at 6, 10 and 26 weeks

Key secondary outcome(s)

1. Cost effectiveness measured at 6 months
2. Operation of the NMS measured 1 year from first recruited patient
3. Patients understanding of their medicines measured at 10 weeks
4. Pharmacovigilance measured 1 year from first recruited patient
5. Professional relationships measured 1 year from first recruited patient
6. Stakeholder experience measured 1 year from first recruited patient

Completion date

28/02/2014

Eligibility**Key inclusion criteria**

1. They are community dwelling patients eligible for NMS (i.e. aged from 14 years starting a new medicine for asthma/COPD, diabetes (Type 2), antiplatelets/anticoagulants or hypertension).
2. There is no upper age limit for providing the NMS hence there is no upper limit for patients taking part in the trial
3. They are able to understand patient/participant study documents
4. They are able and willing to provide informed assent/consent
5. The pharmacist will provide the patient with details of the study to in order to allow the patient to make an informed decision to take part into the study or not
6. Male and female participants

Participant type(s)

Patient

Healthy volunteers allowed

No

Age group

Adult

Sex

All

Key exclusion criteria

1. Younger patients who may not be able to understand the NMS service and/ or consenting procedure
2. Patients collecting a repeat prescription for a medicine for asthma/COPD, type 2 diabetes mellitus (T2DM), antiplatelets/anticoagulants or hypertension
3. Patients collecting a medicine where the only change from the previous medicine involves a dosage or formulation change only
4. Participants who are unable to understand patient/participant study documents
5. Participants who are unable and unwilling to provide assent/consent

Date of first enrolment

16/07/2012

Date of final enrolment

28/02/2014

Locations

Countries of recruitment

United Kingdom

England

Study participating centre

University of Nottingham

Nottingham

United Kingdom

NG7 2RD

Sponsor information

Organisation

University of Nottingham (UK)

ROR

<https://ror.org/01ee9ar58>

Funder(s)

Funder type

Government

Funder Name

National Institute for Health Research (NIHR) - Central Commissioning Facility (UK)

Alternative Name(s)

National Institute for Health Research, NIHR Research, NIHRresearch, NIHR - National Institute for Health Research, NIHR (The National Institute for Health and Care Research), NIHR

Funding Body Type

Government organisation

Funding Body Subtype

National government

Location

United Kingdom

Results and Publications

Individual participant data (IPD) sharing plan

Not provided at time of registration

IPD sharing plan summary

Not provided at time of registration

Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
Results article	10-week follow-up	01/10/2016		Yes	No
Results article	cost effectiveness results	01/12/2017		Yes	No
Results article	26-week follow-up	15/11/2019	27/10/2022	Yes	No
Protocol article	protocol	01/12/2013		Yes	No
Study website	Study website	11/11/2025	11/11/2025	No	Yes